Lannett Sees Boost From Adderall Shortages And Pricing Reprieve
Firm Also Makes ANDA Deals And Gets FDA Nod For Seymour Plant
In a busy period for Lannett, the company has benefited from a US shortage of generic Adderall rivals as well as a “more favorable pricing environment” to enjoy better results than expected – albeit with sales still significantly down on last year.
